论文部分内容阅读
目的探究美沙拉嗪联合柳氮磺吡啶治疗溃疡性结肠炎的临床效果。方法 98例溃疡性结肠炎患者,将其随机分成观察组和对照组,各49例。观察组给予美沙拉嗪联合柳氮磺吡啶治疗,对照组给予柳氮磺吡啶治疗,对比两组患者临床疗效、治疗前后临床症状、镜下黏膜的评分以及不良反应情况。结果两组患者治疗优良率比较,差异有统计学意义(P<0.05)。治疗前,两组临床症状、镜下黏膜评分比较差异无统计学意义(P>0.05);治疗后观察组临床症状、镜下黏膜评分优于对照组(P<0.05)。观察组不良反应发生率为6.12%,低于对照组的20.41%(P<0.05)。结论溃疡性结肠炎通过美沙拉嗪、柳氮磺吡啶治疗,临床效果较佳,不良反应情况少,值得临床深入推广。
Objective To investigate the clinical efficacy of mesalazine combined with sulfasalazine in the treatment of ulcerative colitis. Methods A total of 98 patients with ulcerative colitis were randomly divided into observation group and control group, with 49 cases in each. The observation group was given Mesalazine combined with sulfasalazine and the control group was treated with sulfasalazine. The clinical efficacy, clinical symptoms, microscopic mucosa scores and adverse reactions before and after treatment were compared between two groups. Results The two groups of patients treated excellent rate, the difference was statistically significant (P <0.05). Before treatment, there was no significant difference in clinical symptoms and microscopic mucosal scores between the two groups (P> 0.05). After treatment, the clinical symptoms and microscopic mucosal scores in the observation group were better than those in the control group (P <0.05). The incidence of adverse reactions in the observation group was 6.12%, lower than 20.41% in the control group (P <0.05). Conclusions Ulcerative colitis is treated by mesalazine and sulfasalazine. The clinical effect is better and the adverse reactions are less. It deserves to be popularized clinically.